Trimetazidine是一种亲脂性piperazine衍生物，用于治疗心绞痛。
Cas No.:5011-34-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Trimetazidine is a lipophilic piperazine derivative, which is used for angina pectoris [1]. Trimetazidine acts by selectively inhibiting mitochondrial long-chain 3-ketoacyl-CoA thiolase (HADHA), and in turn, inhibits β-oxidation of fatty acids and promotes glucose utilization, improving cardiac energy metabolism[2]. Trimetazidine has been widely used in animal models to enhance the contraction and relaxation functions of the heart and to improve the recovery of cardiac dysfunction caused by ischemia-reperfusion[3].
In vitro, Trimetazidine treatment for 24h significantly inhibited the viability of PANC-1 cells, with an IC50 value of 3.98mM [4]. Treatment of MCF-7 cells with Trimetazidine (250μM) in combination with paclitaxel (1μM) for 72 hours significantly induced apoptosis and decreased ATP levels in the cells[5].
In vivo, Trimetazidine treatment via oral administration at a dose of 7.2mg/kg/day for 3 days significantly reduced the oxidative stress in the brain and liver of mice induced by lipopolysaccharide (200μg/kg)[6]. A single intraperitoneal injection of 7.2mg/kg of Trimetazidine for 24 hours significantly inhibited the acute gastric mucosal injury induced by indomethacin in rats and enhanced the gastric acid secretion response[7]. Oral administration of 20mg/kg/day for 28 days reversed the hypertension and left ventricular dysfunction caused by sunitinib in mice[8].
References:
[1] Jain S, Bharal N, Mediratta P K, et al. Trimetazidine exerts protection against increasing current electroshock seizure test in mice[J]. Seizure, 2010, 19(5): 300-302.
[2] Chrusciel P, Rysz J, Banach M. Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease[J]. Drugs, 2014, 74(9): 971-980.
[3] Dimitrova D, Manolov S, Ivanov I, et al. Trimetazidine–Profen Hybrid Molecules: Synthesis, Chemical Characterization, and Biological Evaluation of Their Racemates[J]. Pharmaceuticals, 2025, 18(9): 1251.
[4] Şekeroğlu Z A, Şekeroğlu V, Işık S, et al. Trimetazidine alone or in combination with gemcitabine and/or abraxane decreased cell viability, migration and ATP levels and induced apoptosis of human pancreatic cells[J]. Clinics and Research in Hepatology and Gastroenterology, 2021, 45(6): 101632.
[5] Atlı Şekeroğlu Z, Kendigelen E, Şekeroğlu V, et al. Effects of trimetazidine on anticancer activity and toxicity of abraxane in MCF-7 breast cancer cells[J]. Rendiconti Lincei. Scienze Fisiche e Naturali, 2022, 33(4): 879-888.
[6] Abdel-Salam O M E, Mohammed N A, Sleem A A. The effects of trimetazidine on lipopolysaccharide-induced oxidative stress in mice[J]. EXCLI journal, 2011, 10: 162.
[7] Abdel-Salam O M E, El-Batran S. Pharmacological investigation of trimetazidine in models of inflammation, pain and gastric injury in rodents[J]. Pharmacology, 2005, 75(3): 122-132.
[8] Yang Y, Li N, Chen T, et al. Trimetazidine ameliorates sunitinib-induced cardiotoxicity in mice via the AMPK/mTOR/autophagy pathway[J]. Pharmaceutical biology, 2019, 57(1): 625-631.
Trimetazidine是一种亲脂性piperazine衍生物，用于治疗心绞痛[1]。Trimetazidine通过选择性抑制线粒体长链3-ketoacyl-CoA thiolase (HADHA)，进而抑制脂肪酸的β-氧化并促进葡萄糖利用，改善心脏能量代谢[2]。Trimetazidine已被广泛用于动物模型，以增强心脏的收缩和舒张功能，并改善缺血再灌注引起的心功能障碍的恢复[3]。
在体外，Trimetazidine处理24小时显著抑制了PANC-1细胞的活力，IC50值为3.98mM[4]。用250μM的 Trimetazidine联合1μM紫杉醇处理MCF-7细胞72小时，显著诱导了细胞凋亡并降低了细胞内的ATP水平[4]。
在体内，每日口服7.2mg/kg剂量的Trimetazidine，连续3天，显著降低了脂多糖(200μg/kg)诱导的小鼠大脑和肝脏中的氧化应激[6]。单次腹腔注射7.2mg/kg的Trimetazidine 24小时，显著抑制了indomethacin诱导的大鼠急性胃黏膜损伤，并增强了胃酸分泌反应[7]。每日口服20mg/kg的Trimetazidine，连续28天，逆转了sunitinib诱导的小鼠高血压和左心室功能障碍[8]。
| Cell experiment [1]: | |
Cell lines | PANC-1 cells |
Preparation Method | PANC-1 cells were maintained in high glucose DMEM supplemented with 10% FBS, high glucose (25mM), 100units of penicillin, and 100µg/ml streptomycin in a humidified incubator at 37°C and 5% CO2. PANC-1 cells were seeded in a 96-well plate at the density of 1×104 cells/well. The cells were treated with different concentrations (0.01, 0.05, 0.1, 1 and 10mM) of Trimetazidine for 24h, 48h and 72h. Cell proliferation was analyzed. |
Reaction Conditions | 0.01, 0.05, 0.1, 1 and 10mM; 24h, 48h and 72h |
Applications | Trimetazidine treatment significantly inhibited cell proliferation of PANC-1 cells in a dose and time-dependent manner. |
| Animal experiment [2]: | |
Animal models | 129S1/SvImJ mice |
Preparation Method | 129S1/SvImJ mice were housed in large polycarbonate maternity cages on ventilated racks at 22-23°C and kept under a 12:12 light/dark cycle. Food and water were freely available. Eighteen male 8-week-old mice were used in the experiment, and mice were randomized into 3 groups of 6. The sunitinib group received 40mg/kg/day of sunitinib via oral gavage for 28 days; sunitinib-Trimetazidine co-administration group received 40mg/kg/day of sunitinib and 20mg/kg/day of Trimetazidine for 28 days, while control groups received daily administration of the vehicle at the corresponding volume. Samples of mouse hearts were collected for analysis. |
Dosage form | 20mg/kg/day for 28 days; i.p. |
Applications | Trimetazidine treatment significantly ameliorated sunitinib-induced left ventricular dysfunction and cardiomyocyte death in mice. |
References: | |
| Cas No. | 5011-34-7 | SDF | |
| 别名 | 曲美他嗪 | ||
| 分子式 | C14H22N2O3 | 分子量 | 266.34 |
| 溶解度 | DMSO : 125 mg/mL (469.32 mM; Need ultrasonic) | 储存条件 | 4°C, protect from light, stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7546 mL | 18.773 mL | 37.546 mL |
| 5 mM | 750.9 μL | 3.7546 mL | 7.5092 mL |
| 10 mM | 375.5 μL | 1.8773 mL | 3.7546 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: An oil
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet